NK CellTech Secures $14 Million in Series A+++ Financing to Advance NK Cell Therapies
China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB...
China-based biotech innovator NK CellTech has successfully closed its Series A+++ financing round, raising RMB...
China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership...
NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it...
NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received...
Shanghai-based NK Celltech and RongCan Biotech have entered into a partnership agreement to establish a...